11028-71-0
11028-71-0
Chemical Structure
Biological Activity: Concanavalin A can be coupled to agarose to form Concanavalin A (agarose) (HY-P2149A). Concanavalin A (ConA) is a selective, competitive binding agent that targets specific carbohydrate structures containing glucose and mannose; it acts as a mitogen and exhibits varying degrees of cytotoxicity, hepatotoxicity, and teratogenicity. Concanavalin A is also utilized for in vivo blood glucose monitoring in the context of diabetes[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Concanavalin A | 94% | Concanavalin A can be coupled to agarose to form Concanavalin A (agarose) (HY-P2149A). Concanavalin A (ConA) is a selective, competitive binding agent that targets specific carbohydrate structures containing glucose and mannose; it acts as a mitogen and exhibits varying degrees of cytotoxicity, hepatotoxicity, and teratogenicity. Concanavalin A is also utilized for in vivo blood glucose monitoring in the context of diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Concanavalin A (agarose) | Concanavalin A (agarose) is composed of Concanavalin A (HY-P2149) conjugated with agarose. Concanavalin A (ConA) is a selective competitive binder targeting the specific carbohydrate structures of glucose and mannose, inducing mitosis, and exhibiting certain cytotoxicity, hepatotoxicity, and teratogenicity. Concanav in A (agarose) can be used for in vivo blood glucose monitoring in diabetes, and for "fishing out" specific glycoproteins or removing sugar impurities from complex samples. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ballerstadt R, et al. Concanavalin A for in vivo glucose sensing: a biotoxicity review. Biosens Bioelectron. 2006 Aug 15;22(2):275-84. [Content Brief]
- [2]. Li W, et, al. Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics. Biochem Biophys Res Commun. 2011 Oct 22;414(2):282-6. [Content Brief]
- [3]. Cantelli A, et al. Concanavalin A-Rose Bengal bioconjugate for targeted Gram-negative antimicrobial photodynamic therapy. J Photochem Photobiol B. 2020 Mar 13;206:111852. [Content Brief]
- [4]. Zhou Y, et al. The Protective Effect of Resveratrol on Concanavalin-A-Induced Acute Hepatic Injury in Mice. Gastroenterol Res Pract. 2015;2015:506390. [Content Brief]
